TherapeuticsMD (TXMD) Reports In-Line Q4 EPS

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $5.09 million versus the consensus estimate of $5 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
• Ennis (EBF) Misses Q2 EPS by 2c